Abstract
Objectives We used linked individual-level data from national registries to compare the risk of severe outcomes among unvaccinated COVID-19 cases <18 years between waves of the SARS-CoV-2 Alpha, Delta and Omicron variants in Norway.
Methods Our outcomes were hospitalisation with acute COVID-19 or multisystem inflammatory syndrome in children (MIS-C). We calculated adjusted risk ratios (aRR) with 95% confidence intervals (CIs) using multivariable log-binomial regression, adjusting for variant wave, demographic characteristics and underlying comorbidities.
Results We included 10,538 Alpha (21 hospitalised with acute COVID-19, 7 MIS-C), 42,362 Delta (28 acute COVID-19, 14 MIS-C) and 82,907 Omicron wave cases (48 acute COVID-19, 7 MIS-C). The risk of hospitalisation with acute COVID-19 in cases <1 year was lower in the Delta (aRR: 0.28, 95% CI: 0.16–0.89) and Omicron wave (aRR: 0.41, 95% CI: 0.20–0.81), compared to the Alpha wave. We found no difference in the risk for this outcome for Omicron compared to Delta in any age group. The risk of MIS-C was lower in the Omicron wave compared to the Alpha (aRR: 0.09, 95% CI: 0.03–0.27) and Delta wave (aRR: 0.26, 95% CI: 0.10–0.63).
Conclusions We found no evidence of a difference in the risk of hospitalisation due to acute COVID-19 among unvaccinated cases <18 years for Omicron compared to Delta, but a reduced risk among cases <1 year in Omicron and Delta waves, compared to Alpha. Results also suggest a decrease in the risk of MIS-C in the Omicron wave compared to the Alpha and Delta waves.
Article Summary We compare the risk of severe outcomes in unvaccinated COVID-19 cases <18 years between waves of the SARS-CoV-2 Alpha, Delta and Omicron variant in Norway.
What’s Known on This Subject Currently, limited evidence suggests no clear difference in the risk of severe disease outcomes among children infected with different SARS-CoV-2 variants. The risk of multisystem inflammatory syndrome in children following infection with the Omicron variant has not been quantified.
What This Study Adds We find a lower risk of hospitalisation due to acute COVID-19 among cases <1 year in the Delta and Omicron waves compared to the Alpha wave, and a lower risk of multisystem inflammatory syndrome in the Omicron wave, in Norway.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was undertaken as part of routine work at the Norwegian Institute of Public Health. No specific funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for studies on the risk of severe disease by SARS-CoV-2 variant based on data from the national preparedness registry for COVID-19 was granted by Regional Committees for Medical Research Ethics - South East Norway, reference number 249509.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: The authors declare that they have no competing interests.
Funding: This research was undertaken as part of routine work at the Norwegian Institute of Public Health. No specific funding was received.
Data Availability
The dataset analyzed in the study contains individual-level linked data from various central health registries, national clinical registries, and other national administrative registries in Norway. The researchers had access to the data through the national emergency preparedness registry for COVID-19 (Beredt C19), housed at the Norwegian Institute of Public Health (NIPH). In Beredt C19, only fully anonymized data (i.e. data that are neither directly nor potentially indirectly identifiable) are permitted to be shared publicly. Legal restrictions therefore prevent the researchers from publicly sharing the dataset used in the study that would enable others to replicate the study findings. However, external researchers are freely able to request access to linked data from the same registries from outside the structure of Beredt C19, as per normal procedure for conducting health research on registry data in Norway. Further information on Beredt C19, including contact information for the Beredt C19 project manager and information on access to data from each individual data source, is available at https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/.
Abbreviations
- VOC
- Variant of concern
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- COVID-19
- Coronavirus disease
- MIS-C
- Multisystem inflammatory syndrome in children
- LoS
- Length of stay
- ICU
- intensive care unit
- aRR
- Adjusted risk ratio
- CI
- Confidence interval
- PCR
- Polymerase chain reaction
